Intellectual Property - March 4, 2016
EPO has issued 4 new patents to Nuevolution
Swedish Nuevolution announces that the European Patent Office has issued four new patents to the company. In the Q2 2015/2016 report, Nuevolution announced that it was expecting three patents to be granted. Four patents (EP 1905829, EP 2305808, EP 2186897 and EP 1539980) from three different patent families have now issued in Europe. Nuevolution continues […]
Intellectual Property - January 17, 2016
Sobi’s Orfadin granted European patent
Swedish Orphan Biovitrum yesterday announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin (nitisinone) oral suspension formulation, which was approved by the European Commission for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) in 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive […]
Intellectual Property - November 12, 2015
Another milestone towards the UPC
On October 1st, seven EU member states signed the Protocol on the Provisional Application of the Agreement on the Unified Patent Court. In addition, a number of other states affirmed their support and are expected to sign the protocol soon. The protocol is another milestone towards the realization of the Unified Patent Court (UPC). The […]
Intellectual Property - July 4, 2015
ITC Investigating Complaint Against Novo Nordisk
A complaint by Baxter back in March that Novo Nordisk’s recently launched hemophilia drug infringed on some of Baxter’s patents prompted an investigation this week by the U.S. International Trade Commission. On Wednesday, Novo Nordisk disputed Baxter’s claims that its Novoeight used substances Baxter developed, Reuters reports, and it told the news service it had […]
Intellectual Property - June 1, 2015
Fungal Nail Drug Gets Patent
An improved formulation of Moberg Pharma’s OTC product for the treatment of fungal nails, sold in the U.S. under the Kerasal Nail® brand, recently received a patent from the European Patent Office, according to Moberg. The patent expires in 2034. The corresponding U.S. patent was also granted earlier this spring and Moberg Pharma is pursuing […]
Intellectual Property - April 2, 2015
Patent for Nail Fungus Drug
The European Patent Office has issued a patent for Moberg PharmaAB’s topical treatment MOB-015 for onychomycosis (toenail fungus). The patent is expected to be in effect until 2032. Moberg Pharma reported positive results last September from a Phase II study of MOB-015 and in January 2015, received similar patent approval in the U.S. “The granted […]
